anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients randomized to Arm 2 will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5- FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC). Patients who have failed gemcitabine previously and were randomized to Arm 2 will not be eligible to receive gemcitabine as a treatment option.
Participants will receive all six blind-coded samples, in the order C, D, E, F, A, B. There will be a minimum of 7 days washout between samples.
The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
The primary aim of this study is to evaluate the effectiveness of the Apollo Neuro Device on remediating clinical symptoms, cognitive deficits and physical symptoms of those patients struggling with persisting post-concussive symptoms. The Apollo Neuro Device offers a convenient novel, non-invasive, non-habit-forming solution to improve performance and recovery under stress by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time. The investigators will carry out a prospective study including any individual over the age of ten years presenting with persisting post-concussive symptoms. An Apollo Neuro Device will be offered as part of a treatment plan to patients with chronic neurological symptoms and will be used as an adjunct along with typical treatment. Patients will follow-up for a comprehensive evaluation, per discretion of specialty physicians and weekly symptom surveys will also be emailed to patients to track status. The results of this study will further the understanding of autonomic dysfunction symptomology and recovery and evaluate the effect of nerve stimulation as a means of mediating autonomic nervous system dysfunction in these patients.
The purpose of this study is to investigate the ingredients and mechanisms through which Dalbergiae Odoriferae Lignum (DOL) reduces adriamycin-induced cardiotoxicity. DOL's ingredients and drug targets were acquired from Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), and adriamycin-induced cardiotoxicity disease targets were gathered from GeneCards and National Center for Biotechnology Information (NCBI). The therapeutic targets of DOL against adriamycin-induced cardiotoxicity were identified by intersecting drug and disease targets. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) were conducted using R. Subsequently, core targets were determined and used for molecular docking with DOL ingredients. In vitro and in vivo experiments validated DOL's primary ingredients against adriamycin-induced cardiotoxicity efficacy. Western blot and immunohistochemistry verified its impact on target protein. After intersecting 530 drug targets and 51 disease targets, 19 therapeutic targets for DOL alleviated adriamycin-induced cardiotoxicity were received. Molecular docking demonstrated that DOL primary ingredient formononetin had a robust binding affinity for nitric oxide synthase 3 (NOS3). Experimental results showed that formononetin effectively mitigated adriamycin-induced cardiotoxicity. Additionally, western blot and immunohistochemistry showed that formononetin improved NOS3 expression. The network pharmacology and experimentation suggest that the primary ingredient of DOL, formononetin, may target NOS3 to act as a therapeutic agent for adriamycin-induced cardiotoxicity.
Systemic cobalt-chromium (Co-Cr) toxicity following a total hip replacement is a rare complication that may sometimes lead to fatal consequences. We report a case of a 64-year-old woman, who presented with Co-Cr toxicity after revision of fractured ceramic components with metal-on-polyethylene. Systemic toxicity occurred a year after surgery and was expressed brutally with mostly central neurological symptoms. Revision surgery allowed rapid regression of all symptoms. Prosthetic revision with a metal bearing surface after a history of fracture of the ceramic bearing component should be avoided. Orthopedic surgeons and the different medical actors should be aware of this rare but serious complication to allow earlier management. Above all, multidisciplinary management is primordial to allow correct diagnosis and appropriate treatment.
PROBLEM TO BE SOLVED: To provide compounds useful as Raf protein kinase inhibitors.SOLUTION: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. In certain other embodiments, the invention provides pharmaceutical compositions comprising a compound of the invention, wherein the compound is present in an amount effective to inhibit Raf activity. In certain other embodiments, the invention provides pharmaceutical compositions comprising a compound of the invention and optionally further comprising an additional therapeutic agent. In yet other embodiments, the additional therapeutic agent is an agent for the treatment of cancer.
The investigators designed a prospective randomized study to compare the clinical safety and efficacy of maggot debridement therapy (MDT) and conventional dressing therapy (CDT). This study is scheduled from July 2016 to February 2017. Patients, aged from 18-80, who suffered from type 2 diabetic mellitus foot ulcers with Grade 1 or Grade 2 according to the Wagner classification could be the participants of this study. A sample of 138 participants was calculated based on the morbidity of diabetic foot ulcers, accounting for estimated 10% attrition rate. The glycemic control is important for the validity of study results. A specific team of endocrine doctors will manage the blood glucose of participants of two groups within the range of 7-10 mmol/L.

Participants will be allocated into MDT group and CDT group randomly according to the random number table. For MDT-participants, bio-bags containing sterilized, live, medicinal Lucilia sericata larvae will be placed on the wound of ulcers. For CDT-participants, conventional dressing (disinfected by iodophor, dressed by gauze ) will be performed ordinally. Every 3 days the procedures of two groups will be performed and wounds assessment will be done until the wounds closure is achieved. The wounds assessment, including measurement of the area of wound surface and bacterial culture, will be performed by a specific team of microsurgical doctors. The outcome measures include wound healing time (days) and the time negative bacterial culture occurs (days). The secondary outcome measures include the area of wound surface (cm2), treatment related pain, comfort of the dressing and adverse events.
One such enzyme known as VAP-1 (vascular adhesion protein-1) is expressed at high levels in liver endothelial cells and studies involving blockage of VAP-1 activity have demonstrated it is involved in a reaction where break down products such as hydrogen peroxide and ammonia active signalling pathways to assist in the movement of cells from blood vessels to the liver. VAP-1 levels become elevated during chronic inflammation in blood vessels of the gut, tonsils, skin and synovium albeit most selectively in liver. Recently, circulating VAP-1 has been demonstrated to be elevated in certain liver diseases particularly alcoholic liver disease. Initial animal studies have shown that activity of the enzyme SSAO (Semicarbazide-sensitive amine oxidase) can be effectively blocked by caffeine administration and that caffeine also blocks the activity of fat cells, known as adipose cells, thus protective against obesity too. SSAO arises from the same family of enzymes as VAP-1 thus importantly shares transferable properties. This information led to small, experimental studies in human liver that corroborate these findings but did not show how caffeine was affecting VAP-1 in the blood.
Durvalumab (750 mg IV Q2W) was to be given for up to 5 doses. Two cycles of neoadjuvant oxaliplatin (130 mg/m\^2 IV)/capecitabine (1250 mg/m\^2/day given orally) chemotherapy were to be administered before surgery. Subjects were to undergo surgery 6 to 8 weeks after completing chemotherapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions) once recovered from surgery, provided that this was within 3 months of surgery.
PURPOSE:To assay an objective substance with high sensitivity, by containing either one of apoenzyme and the corresponding coenzyme in a microcapsule receiving lytic action by antigen/antibody reaction and containing the other one outside the microcapsule. CONSTITUTION:Apoenzyme and coenzyme are separately received inside and outside a microcapsule. For example, as the microcapsule, a red corpuscle is used and apoglucose oxidase is used as the substance included in the microcapsule an the absorbancy of the reaction solution is measured at a wavelength of 600nm. 10mul of the microcapsule having anti-T4 antibody preliminarily bonded to the surface thereof and 10mul of a solution containing a complement, coenzyme and glucose are mixed with 10mul of a solution containing T4 at known concn. to perform reaction for 20min. After 20min, 20mul of a solution containing peroxidase and 4-aminoantipyrine diethylaniline and 950mul of a 50mMKH2PO4 buffer solution are mixed with the reaction solution to perform reaction for 20min. By this method, absorbancy increases as T4 increases and a T4<-> calibration curve can be formed.
The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
A process is disclosed for producing moulded, pressed dose units with retarded r elease of a therapeutic active ingredient having compression pressure dependent self-retarding properties. In order to pro duce dose units having a very uniform. essentially linear and reproducible constant release of the active ingredient, the active in gredient is reduced during a first step to particles. with a fraction of an additive that inhibits or compensates its self-retarding p roperties. so that mouldings formed with these particles with no further additives have a rapid release in relation to the desired retard ed release in the pressure range required to compress the dose units. Then, during a second step. the particles are moulded w ith a retardant into dose units. Corresponding dose units are also disclosed.
Postoperative education will be provided with 3 short videos that will be accessible to patients on all social media platforms and through MyChart with no scheduled in person postoperative visits. Patients will have a one time visit with either nurse or orthopaedic technician for suture removal 10-14 days from surgery if the participant has nonabsorbable sutures placed during surgery.
The trial will recruit 80 treatment-naive HIV-infected patients with chronic hepatitis C coinfection from two HIV treatment centers in Vietnam. Patients will be randomized to receive either raltegravir or efavirenz, both in combination of tenofovir and emtricitabine, as first-line HIV therapy over a period of 72 weeks. The primary endpoint is the rate of alanine aminotransferase (ALT) elevation during the 72 week study period. Secondary endpoints include rates of virological suppression, CD4 count change, numbers of AIDS events and death, rates of fasting glucose and cholesterol measures, neurocognitive function and levels of immune activation. Patients will be followed monthly for the first 3 months and every 3 months thereafter. At the end of the trial period, patients will be transferred to the National HIV treatment program for continuation of HIV therapy.
Patients following cardiac surgery will be part of the study. Patients will be randomized in control and case groups. Control group receive standart discharge eduation from the nurses of the hospital, they will be interviewed by the researcher to gather general information and also information about recovery and quality of life. Case group will be given a discharge education by the researcher before discharge. After education patients will be given a booklet and a mobile application with the neccasary discharge information. Both groups will be followed for 12 weeks by monthly phone calls. In the last call recovery and quality of life will be reassesed.
FIELD: medicine, immunology, oncology. SUBSTANCE: monoclonal antibody IKO25 exhibiting specificity to antigen MIS1 relates to IgG1 and has association constant 3 x 10 -5  M determined in model of human lung cancer cultured cells OAT75. Based on monoclonal antibody IKO25 antitumor agent is developed that comprises 0.5% of IKO25, 2.0% of polysorbate-80 and saline phosphate buffer, the balance. Invention allows to carry out the selective effect on tumor cells by intravenous administration of preparation. Invention can be used for immunotherapy of malignant tumors. EFFECT: valuable medicinal properties of agent. 3 cl
Before use, store OMNITROPE vials and cartridges refrigerated at 2° to 8°C (36° to 46°F) in the original carton to protect from light. Do not freeze.

After first use, the OMNITROPE cartridge should remain in the pen and kept the original carton in a refrigerator at 2° to 8°C (36° to 46°F) for a maximum of 28 days (see Table 11). Discard unused portions in the cartridge after 28 days.

After reconstitution of the lyophilized powder, the contents of the OMNITROPE vial must be used within 21 days. After the first injection, store the vial in the original carton in a refrigerator at 2° to 8°C (36° to 46°F) (see Table 11). Discard unused portions after 21 days.
PURPOSE:To provide the subject preparation effective for treating and preventing hypertension by compounding a decapeptide or octapeptide contained in the hydrolyzate solution of the extracted solution of Bacillus.stearothermophilus. CONSTITUTION:The subject preparation contains a decapeptide of formula I or II or an octapeptide of formula III. The peptides of formula I-III are prepared e.g. by a method comprising continuously culturing a bacterium strain such as Bacillus.stearothermophilus NCA 1503, self-digesting the obtained bacterial cells to give an extraction solution, acid-hydrolyzing the solution in a 1M acetic acid-20mM hydrochloric acid mixture at 120 deg.C for 1 hour and subsequently isolating and purifying the hydrolization product. The peptides may be prepared by a chemical synthetic method. The peptides are orally administered in various shapes together with a preparation carriers, excipient, binder, etc., or intravenously administered in a shape of intravenous injection in a dose of 0.001-10mg/kg one - four times a day.
The invention belongs to the technical field of medicines, and relates to an application of ticagrelor as a PI3K kinase inhibitor and as a synergist or a drug resistance reversal agent of an anti-tumor chemotherapeutic drug, and an anti-tumor pharmaceutical composition containing ticagrelor. Ticagrelor can effectively inhibit the activity of four subtype kinases of PI3K kinase, and IC thereof  50  The value is 2. mu.M-6. mu.MMeanwhile, ticagrelor can obviously inhibit phosphorylation of key proteins of mTORC1 and mTORC2 signal pathways downstream of PI 3K. Ticagrelor can improve the killing property of some antitumor chemotherapeutic drugs on tumor cells, also can increase the sensitivity of drug-resistant tumor cells on chemotherapeutic drugs and reverse the multidrug resistance of tumors; ticagrelor can reduce the dosage of chemotherapeutic drugs, thereby reducing the toxic and side effects of the chemotherapeutic drugs. The minimum effective dose of ticagrelor is 50 mg/kg. The anti-tumor pharmaceutical composition comprises an anti-tumor chemotherapeutic medicament and ticagrelor, wherein the mass ratio of the anti-tumor chemotherapeutic medicament to the ticagrelor is as follows: 1: 1.25-1: 200.
Vitamin E is obtained by a process in which fatty acid containing material which has been obtained by the saponification of oils or fats containing Vitamin E, is subjected to distillation so that the fatty acids pass over as distillate and the Vitamin E remains undistilled and is then concentrated, the distillation being carried out under mild conditions such that the Vitamin E is not subjected to substantial decomposition.  The freely available Vitamin E may be converted into undistillable esters thereof which remain in the distillation residue.  Distillation may be effected at 170-260 DEG C. in vacuo, preferably with the aid of steam, or by high vacuum distillation.  As starting materials there may be used vegetable oils and fats, e.g. wheatgerm oil and maizegerm oil, cottonseed, soya oil, linseed oil, sunflower oil and nut oil.ALSO:Animal feeds comprise vitamin E concentrates which have been obtained by distilling off the fatty acids from the material obtained by the saponification of oils and fats, e.g. wheat germ, maize germ, cottonseed, soya, linseed, sunflower and nut oils. The concentrates may be enriched by the addition of nutrient salts, clover, fish meal, other vitamins and trace substances.
FIELD: veterinary science. SUBSTANCE: aqueous pharmaceutical solutions for injection administration to recipients have danofloxacin or its pharmaceutically acceptable salts and magnesium or zinc compound, high-molecular cosolvent and an antioxidant optionally. The solution has zinc oxide or acetate as zinc compound and magnesium oxide or chloride as magnesium compound. Method of treatment of bacterial infection involves the subcutaneous administration of indicated pharmaceutical solution to recipient that provides the improved tolerance in injection sites. EFFECT: enhanced effectiveness of the preparation. 12 cl, 21 ex
This would be an open label, single arm, single centre, phase II study designed to evaluate the efficacy of 177Lu-DOTA0-Tyr3-Octreotate in Metastatic NPC.

Patients will first need to go for a 68Ga-DOTATATE scan to determine if they are suitable for 177Lu-DOTA0-Tyr3-Octreotate therapy. A'Hern single stage phase II design (A'Hern, 2001) will be used for conducting the trial. The null hypothesis that the true PFS rate at 6 months is 10% will be tested against the alternate hypothesis of 25%. A total number of 25 patients will be recruited. If there are 5 or more patients who are alive and progression free among these 25 patients at 6 months, we reject the null hypothesis and claim that the treatment is promising.

The design controls the type I error rate at 9.8% and yields a power of 78.6% when the true PFS rate at 6 months is 25%. The first 5 patients will receive 180mCi of 177Lu-DOTA0-Tyr3-Octreotate for the first cycle followed by 200mCi for the remaining 3 cycles if there are no \> Grade 2 toxicities after the first cycle. If there are \>G2 toxicities, the remaining cycles will proceed at 180mCi. A safety review will be done after the first 5 patients. If there are no significant toxicities, the remaining patients will receive 200mCi for 4 cycles. If there are significant toxicities in patients receiving 200mCi for the 2nd to 4th cycle, the remaining patients will receive 180mCi for 4 cycles. If there are significant toxicities in patients receiving 180mCi for the 2nd to 4th cycle, the remaining patients will receive 160mCi for 4 cycles. Dosimetry scans will be done after each cycle of 177Lu-DOTA0-Tyr3-Octreotate at 1h and 96h. Safety and tolerability of 177LuDOTA0-Tyr3-Octreotate will be assessed for the duration of study treatment.

FDG PET/CT scan and 68Ga-DOTATATE scan will be performed at baseline and after cycle 1 (week 4) and cycle 4 (week 28). CT scans will be done at week 12, 24, then 3-monthly starting from week 40. 177Lu-DOTA0-Tyr3-Octreotate treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted. A treatment cycle is eight weeks (56 days) and will be repeated without therapy interruption for 4 cycles unless there is dose limiting toxicities.
All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index \<3% on pH-metry. Antacid therapy will be discontinued.
Therapeutic TSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.
Insulin glulisine is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12). Insulin glulisine differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Insulin glulisine has a molecular weight of 5.823 kDa.

APIDRA (insulin glulisine) injection is a sterile, aqueous, clear, and colorless solution for subcutaneous or intravenous use. Each milliliter of APIDRA contains 100 units insulin glulisine, metacresol (3.15 mg), polysorbate 20 (0.01 mg), sodium chloride (5 mg), tromethamine (6 mg), and water for injection. APIDRA has a pH of approximately 7.3. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.